The DYNC2LI1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with disruption of the DYNC2LI1 gene, creating a loss-of-function model for studying cytoplasmic dynein-2 biology. The polyclonal format avoids clonal artifacts, offering a heterogeneous genetic background suitable for investigating primary cilium function and associated signaling pathways.
The SK-HEP-1 host cell line, derived from the ascitic fluid of a liver adenocarcinoma patient, is a well-characterized model for hepatocellular carcinoma (HCC). These hepatic adenocarcinoma epithelial cells retain key epithelial features and are widely used in liver cancer research, including studies on tumorigenesis and the role of primary cilia in hepatic malignancy.
DYNC2LI1 encodes a light intermediate chain of the cytoplasmic dynein-2 motor essential for retrograde intraflagellar transport (IFT) in primary cilia. It interacts with dynein-2 heavy chain DYNC2H1, adaptors WDR34 and WDR60, and IFT-A and IFT-B complexes to power ciliary trafficking. Transcription of DYNC2LI1 is controlled by RFX factors, linking it to the ciliogenesis program. Functional IFT driven by DYNC2LI1 is critical for Hedgehog pathway activation: it facilitates the trafficking of SMO and PTCH1, enabling appropriate processing of GLI1, GLI2, and GLI3 transcription factors that regulate target gene expression. Thus, DYNC2LI1 serves as a key mediator between ciliary motor activity and Hedgehog signal output.
In SK-HEP-1 liver cancer cells, DYNC2LI1 knockout disrupts retrograde IFT, impairing primary cilium assembly and attenuating Hedgehog signaling. This defect is relevant to hepatic adenocarcinoma because abnormal ciliary dynamics and constitutive Hedgehog pathway activity contribute to proliferation, migration, and drug resistance in HCC. Moreover, the knockout model mimics cellular lesions observed in ciliopathies such as short-rib thoracic dysplasia and Jeune syndrome, making it a versatile tool for both cancer and ciliopathy research.
Applications include ciliopathy disease modeling, mechanistic studies of IFT, and dissection of Hedgehog signaling in liver cancer. Representative experiments encompass western blotting for DYNC2LI1, immunofluorescence of ciliary markers (ARL13B, acetylated tubulin), RT-qPCR for GLI1 and PTCH1, flow cytometric cell cycle analysis, and migration/invasion assays. RNA-seq can identify broader transcriptomic changes. This polyclonal knockout population provides a robust platform for multifaceted investigations. For further information, please contact Ascent Research.
